Cargando…

Newborn Screening for Pompe Disease: Pennsylvania Experience

Pennsylvania started newborn screening for Pompe disease in February 2016. Between February 2016 and December 2019, 531,139 newborns were screened. Alpha-Glucosidase (GAA) enzyme activity is measured by flow-injection tandem mass spectrometry (FIA/MS/MS) and full sequencing of the GAA gene is perfor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ficicioglu, Can, Ahrens-Nicklas, Rebecca C., Barch, Joshua, Cuddapah, Sanmati R., DiBoscio, Brenda S., DiPerna, James C., Gordon, Patricia L., Henderson, Nadene, Menello, Caitlin, Luongo, Nicole, Ortiz, Damara, Xiao, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712483/ https://www.ncbi.nlm.nih.gov/pubmed/33202836 http://dx.doi.org/10.3390/ijns6040089

Ejemplares similares

Newborn Screening for X-Linked Adrenoleukodystrophy: Review of Data and Outcomes in Pennsylvania
por: Priestley, Jessica R. C., et al.
Publicado: (2022)

Utility of Genetic Testing for Confirmation of Abnormal Newborn Screening in Disorders of Long-Chain Fatty Acids: A Missed Case of Carnitine Palmitoyltransferase 1A (CPT1A) Deficiency
por: Dowsett, Leah, et al.
Publicado: (2017)

Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study
por: Ficicioglu, Can, et al.
Publicado: (2020)

Newborn Screening for Pompe Disease
por: Sawada, Takaaki, et al.
Publicado: (2020)

New tools and approaches to newborn screening: ready to open Pandora's box?
por: Ficicioglu, Can
Publicado: (2017)

Development of Newborn Screening for Pompe Disease
por: Hwu, Wuh-Liang, et al.
Publicado: (2020)

The Importance of Succinylacetone: Tyrosinemia Type I Presenting with Hyperinsulinism and Multiorgan Failure Following Normal Newborn Screening
por: Priestley, Jessica R. C., et al.
Publicado: (2020)

Newborn Screening for X-Linked Adrenoleukodystrophy in Nebraska: Initial Experiences and Challenges
por: Baker, Craig V., et al.
Publicado: (2022)

Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via Newborn Screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction
por: Li, Cindy, et al.
Publicado: (2021)

Establishing Pompe Disease Newborn Screening: The Role of Industry
por: Keutzer, Joan M.
Publicado: (2020)

Current status of newborn screening for Pompe disease in Japan
por: Sawada, Takaaki, et al.
Publicado: (2021)

Newborn screening for Pompe disease in Italy: Long-term results and future challenges
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Effects of variability in daily light integrals on the photophysiology of the corals Pachyseris speciosa and Acropora millepora
por: DiPerna, Stephanie, et al.
Publicado: (2018)

Provider Perspectives on the Impact of the COVID-19 Pandemic on Newborn Screening
por: Gold, Jessica I., et al.
Publicado: (2021)

Current Practices for U.S. Newborn Screening of Pompe Disease and MPSI
por: Ames, Elizabeth G., et al.
Publicado: (2020)

The First Year Experience of Newborn Screening for Pompe Disease in California
por: Tang, Hao, et al.
Publicado: (2020)

Lessons Learned from Pompe Disease Newborn Screening and Follow-up
por: Klug, Tracy L., et al.
Publicado: (2020)

Newborn Screening for Pompe Disease in Illinois: Experience with 684,290 Infants
por: Burton, Barbara K., et al.
Publicado: (2020)

Harmonization of Newborn Screening Results for Pompe Disease and Mucopolysaccharidosis Type I
por: Dorley, M. Christine, et al.
Publicado: (2023)

Newborn screening for pompe disease? a qualitative study exploring professional views
por: van El, Carla G, et al.
Publicado: (2014)

The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan
por: Chiang, Shu-Chuan, et al.
Publicado: (2020)

Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening
por: Jackson, David G., et al.
Publicado: (2023)

Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement
por: Degnan, Andrew J., et al.
Publicado: (2019)

Muscle ultrasound: A useful tool in newborn screening for infantile onset pompe disease
por: Hwang, Hsuen-En, et al.
Publicado: (2017)

Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges
por: Smith, Laurie D., et al.
Publicado: (2020)

Social–Emotional Learning for Whom? Implications of a Universal SEL Program and Teacher Well-being for Teachers’ Interactions with Students
por: Sandilos, Lia E., et al.
Publicado: (2022)

Pompes turbomoleculaires
por: Versolatto, B
Publicado: (1982)

Is Newborn Screening the Ultimate Strategy to Reduce Diagnostic Delays in Pompe Disease? The Parent and Patient Perspective
por: Saich, Raymond, et al.
Publicado: (2020)

At-Risk Testing for Pompe Disease Using Dried Blood Spots: Lessons Learned for Newborn Screening
por: Lukacs, Zoltan, et al.
Publicado: (2020)

Biochemical characterization of patients with dihydrolipoamide dehydrogenase deficiency
por: Wongkittichote, Parith, et al.
Publicado: (2023)

Pennsylvania
Publicado: (1896)

Pennsylvania
Publicado: (1896)

Pennsylvania
Publicado: (1896)

Pennsylvania
Publicado: (1896)

Pennsylvania
Publicado: (1896)

Pennsylvania
Publicado: (1899)

Pennsylvania
Publicado: (1899)

Pennsylvania
Publicado: (1899)

Pennsylvania
Publicado: (1899)

Pennsylvania
Publicado: (1896)

Cannot write session to /tmp/vufind_sessions/sess_3j5qf5h5r6vbkcggd3fer3j55i